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Background: Dietary glucose consumption has increased worldwide. Long-term high glucose intake contributes to
the development of obesity and type 2 diabetes mellitus (T2DM). Obese people tend to eat glucose-containing
foods, which can lead to an addiction to glucose, increased glucose levels in the blood and intestine lumen, and
exposure of intestinal enterocytes to high dietary glucose. Recent studies have documented a role for enterocytes
in glucose sensing. However, the molecular and genetic relationship between high glucose levels and intestinal
enterocytes has not been determined. We aimed to identify relevant target genes and molecular pathways
regulated by high glucose in a well-established in vitro epithelial cell culture model of the human intestinal system
(Caco-2 cells).
Methods: Cells were grown in a medium containing 5.5 and 25 mM glucose in a bicameral culture system for
21 days to mimic the human intestine. Transepithelial electrical resistance was used to control monolayer formation
and polarization of the cells. Total RNA was isolated, and genome-wide mRNA expression profiles were determined.
Molecular pathways were analyzed using the DAVID bioinformatics program. Gene expression levels were
confirmed by quantitative reverse transcription polymerase chain reaction (RT-qPCR).
Results: Microarray gene expression data demonstrated that 679 genes (297 upregulated, 382 downregulated) were
affected by high glucose treatment. Bioinformatics analysis indicated that intracellular protein export (p = 0.0069) and
ubiquitin-mediated proteolysis (p = 0.024) pathways were induced, whereas glycolysis/gluconeogenesis (p < 0.0001),
pentose phosphate (p = 0.0043), and fructose-mannose metabolism (p = 0.013) pathways were downregulated, in
response to high glucose. Microarray analysis of gene expression showed that high glucose significantly induced
mRNA expression levels of thioredoxin-interacting protein (TXNIP, p = 0.0001) and lipocalin 15 (LCN15, p = 0.0016)
and reduced those of ATP-binding cassette, sub-family A member 1 (ABCA1, p = 0.0004), and iroquois homeobox
3 (IRX3, p = 0.0001).
Conclusions: To our knowledge, this is the first investigation of high glucose-regulated molecular responses in
an intestinal enterocyte model. Our findings identify new target genes that may be important in the intestinal
glucose absorption and metabolism during high glucose consumption.
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Table 1 Effect of high glucose on cell permeability
Ctrl +Glc p value Significance
TEER (ohm/cm2) 934 ± 32.35 809.5 ± 39.29 0.0707 NS
Normalized OCLN
mRNA levels
1 ± 0.095 0.93 ± 0.10 0.6096 NS
Normalized ZO1
mRNA levels
1 ± 0.064 1.05 ± 0.14 0.7336 NS
Caco-2 cells were grown on collagen-coated inserts in 5.5 and 25 mM glucose
containing DMEMs for 21 days. TEER value was measured before RNA isolation.
Occludin (OCLN) and Zoolin1 (ZO1) mRNA levels were measured by RT-qPCR,
and relative fold changes of gene expression levels were analyzed. Statistical
significance was determined by Student’s t test. Values are expressed as the
mean ± SD; n = 3 independent experiments with three technical replicates
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Consumption of high dietary glucose is a risk factor for
the development of obesity and type 2 diabetes mellitus
(T2DM) in humans [1, 2]. The total number of deaths
attributable to high blood glucose in 2012 was estimated
as 3.7 million, 1.5 million of which were due to diabetes
[3]. High glucose intake leads to postprandial glycemia,
insulinemia, and lipidemia in healthy overweight people
[4]. Moreover, longer exposure to dietary high glucose is
associated with the development of T2DM [5]. These
findings indicate that control of dietary glucose intake is
an important strategy to combat the development of
obesity and T2DM. Recent studies have focused on the
mechanisms controlling blood glucose turnover during
obesity and T2DM. For example, sodium-dependent glu-
cose transporter 1 (SGLT1) is a protein that has been
targeted to control reabsorption of glucose from the kid-
ney [6]. Moreover, hepatic glucose production from
glycogen has been studied as a therapeutic target mo-
lecular pathway in the development of T2DM [7].
Glucose-dependent molecular mechanisms contributing
to obesity and T2DM have been extensively studied in
the adipose tissue, liver, pancreas, and brain. The small
intestine may also be an important tissue to investigate
glucose metabolism during obesity and T2DM, as it can
contribute to systemic glucose production in fasted and
diabetic states [8]. Moreover, the gene expression and
morphology of the small intestine are altered during
obesity [9]. These adaptive changes of the small intestine
may be uncontrolled during high nutrient consumption
and metabolic disease states. The small intestine mainly
consists of enterocytes, which directly interact with diet-
ary nutrients and transfer them into the circulatory sys-
tem [10]. The rate of interaction between nutrients and
enterocytes varies depending on the eating habits of
individuals.
Recent studies suggest that there may be a physiological
interaction between enterocytes and glucose that contrib-
utes to intestinal dietary glucose sensing [9, 11, 12]. In
humans, high dietary glucose consumption elevates
glucose levels in the lumen of the intestine and in
the blood; hence, enterocytes are exposed to high
levels of glucose in both the diet and the blood. This
situation can be continuous in obese people, due to
the consumption of foods containing high levels of
glucose [13]. It is unknown how enterocytes respond
to high glucose levels in either the diet or the blood.
Hence, investigations to improve the understanding of
the adaptive physiological changes of enterocytes in
response to high glucose consumption are warranted.
In this study, we examined the genome-wide molecu-
lar responses of enterocytes to high glucose. Our re-
sults demonstrate that chronic high glucose exposure
influences specific molecular pathways and genes thatmay be important in the control of intestinal glucose
absorption during high glucose consumption.
Results
Effect of high glucose on cellular tight junctions and
measurement of glucose efflux
The monolayer structure formation and tight junction
permeability of Caco-2 cells are commonly evaluated by
measurement of transepithelial electrical resistance
(TEER) along with OCLN and ZO1 gene mRNA levels
[14, 15]. We grew Caco-2 cells in bicameral cell culture
chambers to mimic the human intestine and measured
TEER and OCLN and ZO1 mRNA expression levels to
evaluate the intestinal barrier function of our experi-
mental model. The TEER levels of control and high
glucose-treated 21-day postconfluent Caco-2 cell groups
were not significantly different (Table 1) and neither
were OCLN and ZO1 mRNA levels significantly affected
by high glucose treatment (Table 1). These results dem-
onstrate that high glucose did not interfere with barrier
formation by monolayer Caco-2 cells.
The function of enterocytes involves absorption of
dietary nutrients (nutrient uptake) and their transport
into the blood circulation (nutrient efflux). We tested
cellular glucose efflux under control and high glucose
treatment conditions. Glucose efflux was significantly
increased in the glucose-treated group relative to the
controls at the 90-min (p = 0.0031; 1.4-fold), 120-min
(p = 0.01; 1.4-fold), and 240-min (p = 0.0049; 1.9-fold)
time points (Table 2), suggesting that Caco-2 cells
mimic the human intestine in terms of glucose efflux
in our experimental model.
High glucose alters mRNA expression levels of glucose-
regulated genes
Before genome-wide array analysis was performed, we
tested whether high glucose affected the regulation of
glucose-related genes in Caco-2 cells. Thus, we analyzed
mRNA expression of GLUT2, GLUT5, and SGLT1. mRNA
expression levels of GLUT2 (1.8-fold; p = 0.0001), GLUT5
(1.5-fold; p = 0.0004), and SGLT1 (1.4-fold; p = 0.0053)
Table 2 Cellular glucose efflux
Time (min) Ctrl +Glc p value Significance
0 105.5 ± 4.50 114.5 ± 2.5 0.2225 NS
30 104.5 ± 1.50 121.0 ± 7.0 0.1477 NS
60 103.5 ± 5.50 128.0 ± 2.0 0.0526 NS
90 96.5 ± 2.50 135.5 ± 2.5 0.0031 Yes
120 105.5 ± 4.00 142.5 ± 3.5 0.0195 Yes
240 90.00 ± 5.0 169.5 ± 2.5 0.0049 Yes
The glucose efflux was measured from the basolateral surface of the two
experimental groups at 0-, 30-, 60-, 120-, 180-, and 240-min time points. Results
were given as milligrams per deciliter. Statistical significance was determined by
Student’s t test. Values are expressed as the mean ± SD; n = 3 independent
experiments with three technical replicates
Table 4 Functional analysis of high glucose-regulated up- or
downregulated genes
Upregulated pathways p value Number of genes
Ubiquitin-mediated proteolysis 2.4 × 10−2 7
Protein export 6.9 × 10−3 3
Downregulated pathways
Glycolysis/gluconeogenesis 3.0 × 10−5 10
Pentose phosphate 4.3 × 10−3 5
Fructose and mannose metabolism 1.3 × 10−2 5
Microarray data showed a total of 297 upregulated and 382 downregulated
genes in response to high glucose treatment. The high glucose-regulated
genes were subjected in DAVID bioinformatics analyze program to describe
the functional molecular pathways along with the number of genes in
each pathway
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relative to the controls (Table 3).
Classification of differentially expressed genes and
confirmation of mRNA expression of genes from
molecular pathways
Microarray technology was used to identify genes that were
differentially expressed in experimental samples. When we
compared the control and high glucose-treated groups, we
identified a total of 297 and 382 genes that were signifi-
cantly up- and downregulated, respectively (≥ 1.5-fold
change; p < 0.05) in response to high glucose treatment.
The list of high glucose-regulated genes is available under
GEO accession number GSE97977 ( https://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE97977; Additional file
2: Table S2 and Additional file 3: Table S3). These genes
were used to identify high glucose-regulated molecular
pathways by DAVID bioinformatics program using KEGG
Pathways database. The gene IDs were converted to DA-
VID gene IDs that were associated with particular pathway
annotation terms. The enrichment of molecular pathways
was performed by Benjamini-Hochberg method, and p ≤ 0.
05 was used as a cutoff value in DAVID annotation model.
Intracellular protein export (p = 0.0069) and ubiquitin-
mediated proteolysis (p = 0.024) pathways were identified as
significantly induced, whereas glycolysis-gluconeogenesis
(p < 0.0001), pentose phosphate (p = 0.0043), and fructose-
mannose metabolism (p = 0.013) pathways were signifi-
cantly downregulated by high glucose treatment in Caco-2
cell monolayers after 21 days (Table 4). The detailedTable 3 mRNA expression levels of glucose-regulated genes
Genes Ctrl +Glc p value Significance
GLUT2 1.004 ± 0.035 0.5465 ± 0.055 0.0001 Yes
GLUT5 1.014 ± 0.064 0.6490 ± 0.044 0.0004 Yes
SGLT1 1.023 ± 0.083 0.7186 ± 0.040 0.0053 Yes
Total RNA was isolated from the control and the high glucose-treated (+Glc)
groups. RT-qPCR was performed to analyze relative expression levels of genes
from the two experimental groups. Statistical significance was determined by
Student’s t test. Values are expressed as the mean ± SD; n = 3 independent
experiments with three technical replicatesinformation for high glucose-regulated pathways can be
found in Additional file 4: Figure S2, Additional file 5: Fig-
ure S2, Additional file 6: Figure S3, Additional file 7: Figure
S4, and Additional file 8: Figure S5.
Quantitative reverse transcription polymerase chain
reaction analysis of genes identified by microarray
analysis
Genome-wide mRNA array technology provides valuable
information about the genomic regulation of cells; how-
ever, technical procedures can affect microarray results
[16]. Therefore, we performed RT-qPCR experiments to
confirm the regulation of individual genes from the
identified molecular pathways. In the intracellular
protein export pathway, mRNA levels of SRP14 (1.4-fold;
p = 0.002) and SRP54 (1.8-fold; p = 0.0003) and in the
ubiquitin-mediated proteolysis pathway, mRNA levels of
UBE2L6 (2-fold; p = 0.0007), UBE2Q2 (1.6-fold; p = 0.01),
and SKP1 (1.5-fold; p = 0.03) were significantly increased
in the high glucose-treated group compared with the con-
trols (Table 5). However, RT-qPCR analysis of the SRP72
gene in the protein export pathway did not indicate simi-
lar regulation to that determined by microarray analysis.
We also selected common genes from molecular pathways
that were downregulated by high glucose treatment and
found that mRNA levels of ALDOA (1.5-fold; p = 0.006),
ALDH2 (2.8-fold; p = 0.01), PFKP (2.9-fold; p = 0.0002),
PGAM1 (1.7-fold; p = 0.03), PGD (2.1-fold; p = 0.002), and
PFKFB3 (4.3-fold; p = 0.003) were significantly reduced in
pathways downregulated by high glucose treatment
(Table 5).
Investigation of microarray data on glucose-regulated
genes
We also searched our gene expression array data to find
relevant candidate gene(s) that may be important in en-
terocyte glucose metabolism under high-glucose condi-
tions. High glucose significantly induced levels of
transcription of TXNIP (3.2-fold; p = 0.0001) and LCN15
Table 5 Confirmation of mRNA expression of genes from
molecular pathways
Genes Ctrl +Glc p value Significance
Group1
SRP14 1.008 ± 0.046 1.419 ± 0.102 0.002 Yes
SRP54 1.038 ± 0.101 1.804 ± 0.113 0.0003 Yes
SRP72 1.095 ± 0.20 1.177 ± 0.101 0.7509 NS
Group 2
UBE2L6 1.002 ± 0.151 2.034 ± 0,185 0.0007 Yes
UBE2Q2 1.000 ± 0.136 1.578 ± 0.139 0.01 Yes
SKP1 1.005 ± 0.167 1.516 ± 0.151 0.03 Yes
Group 3
ALDOA 1.000 ± 0.087 0.6652 ± 0.042 0.006 Yes
ALDH2 1.000 ± 0.138 0.3593 ± 0.146 0.01 Yes
PFKP 1.000 ± 0.088 0.3360 ± 0.074 0.0002 Yes
PGAM1 1.000 ± 0,108 0.5777 ± 0.138 0.03 Yes
PGD 1.000 ± 0.101 0.4760 ± 0.066 0.002 Yes
PFKFB3 1.000 ± 0.179 0.2334 ± 0,082 0.003 Yes
The gene expression levels from molecular pathways were analyzed by RT-
qPCR method. The relative changes of mRNA expression levels in the protein
export (group1) and ubiquitin-mediated proteolysis (group2) pathways were
indicated in the table. The mRNA expression of common genes from molecular
pathways that were downregulated by high glucose treatment was shown as
group 3 in the table. Statistical significance was determined by Student’s t test.
Values are expressed as the mean ± SD; n = 3 independent experiments with
three technical replicates
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(5.3-fold; p = 0.0004) and IRX3 (13-fold; p = 0.0001) were
downregulated in the high glucose treatment group
(Table 6).Discussion
In this study, we used the established in vitro Caco-2
monolayer system to model the effects of high glucose
exposure on intestinal enterocytes. The results of TEER
measurement and evaluation of the expression of genes
encoding the tight junction proteins, OCLN and ZO1,
indicated that the cells successfully formed a monolayerTable 6 Glucose-regulated mRNA levels of individual genes
Genes Ctrl +Glc p value Significance
TXNIP 1.000 ± 0.140 3.170 ± 0.146 0.0001 Yes
LCN15 1.000 ± 0.129 5.992 ± 1.270 0.0016 Yes
ABCA1 1.000 ± 0.145 0.1939 ± 0.045 0.0004 Yes
IRX3 1.000 ± 0.153 0.07723 ± 0.027 0.0001 Yes
Microarray data indicated individual candidate genes that might be important
for intestinal glucose metabolism during high glucose consumption. High
glucose treatment significantly induced TXNIP and LCN15 mRNA expression
levels relative to the control group while ABCA1 and IRX3 mRNA levels were
downregulated in the high glucose-treated group. Statistical significance was
determined by Student’s t test. Values are expressed as the mean ± SD; n = 3
independent experiments with three technical replicatesbarrier that was not disrupted by exposure to high glu-
cose levels.
Initial experiments to evaluate the effects of glucose
on known glucose-regulated genes indicated that SGLT1,
GLUT5, and GLUT2 were downregulated in response to
high glucose exposure. The regulations of SGLT1 and
GLUT5 genes in this paper are in contrast with
Mahraoui et al. [17]. They reported that the glucose con-
sumption of early (p29) or late (p198) passages of
Caco-2 cells was different, and the mRNA regulations of
SGLT1, GLUT5, and GLUT2 genes were affected by pas-
sage number of the cells and basal glucose consumption
rate. Northern blot analysis from the same study indi-
cated that 21-day high glucose (25 mM) treatment of
Caco-2 cells can significantly induce SGLT1 and GLUT5
mRNA expression levels compared to low glucose-
treated groups (1 mM). However, GLUT2 mRNA level
was reduced by high glucose treatment, which we
observed similar results for GLUT2 mRNA expression.
There are different steps of experimental approaches
between these two studies. We used polarized Caco-2
cells from 35 to 45 passages and maintained Caco-2 cells
under high-glucose condition for longer time periods.
Moreover, we compared mRNA expression results from
25 and 5.5 mM glucose treatment groups. It seems pos-
sible that these factors might affect the regulation of
SGLT1 and GLUT5 genes. It has been shown that SGLT1
and GLUT2 mRNA expression levels were induced when
glucose level was increased into the lumen of the intes-
tine in in vivo [18, 19]. It has been indicated that intra-
cellular and extracellular factors are involved in the
regulations of glucose transporters [20, 21]. The different
mRNA regulations of SGLT1 and GLUT2 in in vitro and
in in vivo might be due to those factors that are not
predominantly regulated in in vitro models under high
glucose treatment. Despite these differences, we may at
least conclude that high glucose influences the genetic
responses of Caco-2 cells.
Several molecular pathways, including intracellular
protein export and ubiquitin-mediated proteolysis
(upregulated), along with glycolysis/gluconeogenesis,
pentose phosphate, and fructose-mannose metabolism
(downregulated), were identified as responsive to high
glucose in our in vitro enterocyte model. Changes in
these molecular pathways under high-glucose conditions
should also be evaluated at the functional level to deter-
mine the physiological relevance of the findings of the
current study to enterocyte glucose metabolism during
high glucose treatment in vivo.
A search for genes of particular interest among those
identified as regulated by elevated glucose using
genome-wide microarray analysis detected several strong
candidates, including ABCA1, IRX3, TNXIP, and LCN15.
ABCA1 is involved in cellular cholesterol efflux and
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The intestine expresses high levels of ABCA1, indicating
that this tissue is a major cholesterol source for
plasma HDL; indeed, intestinal ABCA1 contributes
30% of circulating HDL cholesterol [22]. High dietary
cholesterol intake in the intestine increases basolateral
ABCA1 mRNA and protein levels in enterocytes [23].
However, high glucose reduces ABCA1 mRNA and
protein levels in the macrophages, decreasing choles-
terol flux from the macrophages to the blood; hence,
glucose influences cholesterol metabolism via control
of ABCA1 gene expression. Our results also demon-
strate that high glucose can reduce ABCA1 mRNA
expression levels in intestinal enterocytes, and levels
of cholesterol efflux from the cells in our experimen-
tal model should be measured to allow definitive con-
clusions to be drawn from our results. Surprisingly,
IRX mRNA expression was also regulated in Caco-2
cells under high glucose treatment, since IRX3 is
highly expressed in the brain and involved in feeding
behavior [24]. Single nucleotide polymorphisms in the
IRX3 gene are reported as strongly associated with
BMI in human subjects [24]. Moreover, IRX3 knock-
out mice had body weights approximately 30% less
than their wild-type littermates [24], suggesting that
the IRX3 gene is closely related to obesity. Glucose-
regulated IRX3 mRNA regulation was shown, for the
first time in our study; however, the function of intes-
tinal IRX3 is unknown, and regulation of IRX3 in the
intestine under high glucose consumption requires
further investigation. High glucose significantly in-
duced mRNA levels of the TXNIP and LCN15 genes.
TXNIP plays a role in glucose uptake and is involved
in glucose production in the mouse liver [25, 26].
TXNIP-mutant mice become hypertriglyceridemic and
hypoglycemic during fasting [27]. These observations
suggest that TXNIP may be an important candidate
intracellular regulator of enterocyte glucose metabol-
ism. There is very limited information about LCN15
in the literature, and its physiological function is
unknown; however, it is a member of the lipocalin
gene family, of which LCN2 is a well-studied member
involved in obesity and diabetes. LCN2, also known
as an adipokine, is secreted from the adipose tissue,
and its expression is elevated in obese humans and
T2DM mouse models [28]. LCN2-null male mice are
protected from high fat diet-induced obesity and insu-
lin resistance [29]. It was concluded that LCN2 may
be an adipose tissue regulator that modulates glucose
metabolism in murine tissues and in the 3T3-L1 adi-
pocyte cell culture model [30]. These studies clearly
suggest that ABCA1, IRX3, TXNIP, and LCN15 may
physiologically interact with high glucose in entero-
cytes. An important finding of the current study isthat intestinal glucose absorption may be controlled
via TXNIP and LCN15.
Conclusions
An important limitation of this study was the use of the
colon carcinoma cell line, Caco-2, as a model of the
human intestine. Although Caco-2 is a cancer cell line, it
is established in the literature as an in vitro model of the
human intestine system, and there are no alternative
non-cancerous human cell lines that function similarly.
The scope of this study was limited to enterocyte glu-
cose metabolism gene regulation during high glucose
treatment; therefore, the study findings should be inter-
preted with caution. However, the results provide valu-
able information regarding the molecular and genetic
responses of enterocytes to high glucose levels, which is
the main nutritional contributor to the development of
obesity and T2DM. Studies of the intestine and obesity
have largely focused on intestinal glucose sensing and
reduced intestinal glucose absorption through delaying
the breakdown of carbohydrates in enterocytes, while
the mechanisms by which enterocytes respond to high
glucose levels have not been investigated previously.
Thus, the identification of candidate genes (for example,
TXNIP) involved in the control of intestinal glucose
absorption during high glucose consumption is import-
ant. Moreover, enterocytes exposed to high glucose may
communicate, possibly via LCN15, with endocrine cells
in the intestine or peripheral tissues. This screen of
glucose-dependent genetic regulation in enterocytes has
identified important target genes and will facilitate
further investigation of the control of glucose metabol-
ism in enterocytes during high glucose intake, which is a
common cause of the progression of obesity and T2DM.
Methods
Culture of Caco-2 cells
The human colorectal adenocarcinoma epithelial cell line,
Caco-2, was purchased from the American Type Culture
Collection (ATCC, HTB-37). Caco-2 cells were main-
tained at 37 °C in a 5% CO2/95% O2 atmosphere. They
were grown in DMEM supplemented with 15% (v:v) fetal
bovine serum (Gibco, Cat. No.: 10500), 1% penicillin and
streptomycin solution with antimycotic (Sigma, Cat. No.:
A5955), and 1% (v:v) nonessential amino acids (Gibco,
Cat. No.: 11140). Cells were separated into two groups:
control (ctrl) and high glucose-treated (+Glc), which were
grown in DMEM cell culture medium containing different
glucose concentrations (selected based on a previous re-
port [31]) as follows: ctrl group 5.5 mM glucose (Sigma,
Cat. No.: D6046) and +Glc group 25 mM glucose (Sigma,
Cat. No.: D6429). Cells were maintained in 5.5 and
25 mM DMEM cell culture media for three passages
(28 days) to acclimate to the different glucose conditions.
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between passages 35 and 45.
Modeling of the human intestinal system and glucose
treatment
When Caco-2 cells are grown in a bicameral cell cul-
ture system, they can polarize to produce apical and
basolateral surfaces [32], mimicking the human small
intestine [33, 34]. Caco-2 cells (106/cm2) from the
control and high glucose-treated groups were seeded
on collagen-coated polytetrafluoroethylene membrane
with 0.4-μm pore size and 1.12 cm2 diameter (Corning,
Cat. No.: 3493). After 3 days of confluent culture, the
cells were grown for an additional 21 days in the
bicameral cell culture system in the indicated DMEM
media. Media were changed every 2 days during the 21-
day experimental period. Transepithelial electrical re-
sistance (TEER) was measured using an Epithelial Volt/
Ohm Meter (EVOM; World Precision Instruments,
USA) to confirm polarization of the monolayer and cell
integrity. The TEER value of polarized Caco-2 cells
should be at least 250 Ω/cm2 [34].
Measurement of cellular glucose efflux
We measured glucose efflux to the basolateral surface of
the Caco-2 cell monolayer to test the function of the small
intestine model. After ctrl and +Glc Caco-2 cells had been
cultured for 21 days, the apical surfaces of the polarized
cell monolayers were maintained in DMEM containing 5.
5 and 25 mM (modeling high dietary glucose consump-
tion) glucose; the basolateral surfaces of both experimen-
tal groups were incubated in DMEM containing 5.5 mM
glucose. Samples were collected from the basolateral sur-
faces of the two experimental groups at 0-, 30-, 60-, 120-,
180-, and 240-min time points. The glucose levels on the
basolateral surfaces of the monolayers were measured
using a Glucose Oxidase Enzymatic Assay kit, according
to the manufacturer’s protocol (Sigma, Cat. No.:
GAGO20). Data were normalized to total protein levels.
Total proteins were extracted from cells using RIPA buffer
[35] and their concentrations determined using a BCA
protein assay kit (Pierce, Cat. No.: 23227).
RNA isolation and RT-qPCR
Total RNA was isolated using RNAzol reagent (MRC, Cat.
No.: RN190), according to the manufacturer’s protocol.
Total RNA samples were dissolved in DEPC water,
followed by measurement of their concentrations using a
NanoDrop instrument (Thermofisher, MA, USA). Each
RNA sample was separated into two aliquots for microarray
analysis and RT-qPCR. One microgram of each RNA sam-
ple was converted to cDNA using a cDNA synthesis kit
(Lifetech, Cat. No.: 4368814). To determine the mRNA ex-
pression levels of genes, RT-qPCR was performed on anABI StepOnePlus instrument (Lifetech, CA, USA) by
SYBR-Green mix (Lifetech, Cat. No.: 4367659). The run-
ning method of RT-qPCR is as follows: 95 °C/10 min, 40 cy-
cles (95 °C/10 s, 60 °C/1 min), and melt curve stage (95 °C/
15 s, 60 °C/1 min). Human cyclophilin A was used as a
housekeeping gene for normalization of mRNA expression
results. Primer sequences are listed in Additional file 1:
Table S1. The 2−ΔΔCt analysis method was applied to
calculate mean fold changes in mRNA levels [36].
Genome-wide microarray analysis
The integrity of RNA samples from each group was
assessed using an Agilent 2100 Bioanalyzer and RNA 6000
Nano reagent (Agilent). RNA samples were converted to
cRNA using an Ambion Illumina Total Prep RNA Ampli-
fication Kit. cRNA samples were loaded onto a microarray
(HumanHT-12 v4 Expression BeadChip) then left over-
night for hybridization. Finally, the BeadChip was read
and analyzed using a microarray laser reader. The signifi-
cance of the mRNA expression between the control and
the high glucose-treated groups was calculated Log2 fold
change of ± 1.5 with p < 0.05.
Gene ontology and statistical analyses
Significantly regulated mRNAs between the control and
the high glucose-treated groups were conducted to DA-
VID Functional Annotation Bioinformatics Microarray
Analysis 6.7 (National Institute of Allergy and Infectious
Diseases), to determine statistically overrepresented mo-
lecular pathways. KEGG Pathways database was used for
functional annotation enrichment analysis. Fisher exact
test was used with selected value (p ≤ 0.05) in DAVID an-
notation system. All the results were expressed as means
± SD. Student t test was performed for relative gene ex-
pression to compare the two groups. GraphPad Prism
(version 6.0 for Windows, GraphPad. CA, USA) was used
to calculate significance between groups.Additional files
Additional file 1: Table S1. The Primer list for RT-qPCR. (PDF 856 kb)
Additional file 2: Table S2. The list of the significantly downregulated
genes under high glucose treatment condition (382 genes). (XLSX 89 kb)
Additional file 3: Table S3. The list of the significantly upregulated
genes under high glucose treatment condition (297 genes). (XLSX 85 kb)
Additional file 4: Figure S1. Ubiquitin mediated proteolysis Pathway
(Upregulated). (TIFF 497 kb)
Additional file 5: Figure S2. Intracellular protein export pathway
(Upregulated). (TIFF 872 kb)
Additional file 6: Figure S3. Glycolysis/Gluconeogenesis Pathway
(Downregulated). (TIFF 416 kb)
Additional file 7: Figure S4. Pentose Phosphate Pathway
(Downregulated). (TIFF 490 kb)
Additional file 8: Figure S5. Fructose and Mannose Metabolism
Pathway (Downregulated). (TIFF 857 kb)
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glucose transporter 1; SKP1: S-phase kinase-associated protein 1; SRP14/54/
72: Signal recognition particle 14 kDa/54 kDa/72 kDa; T2DM: Type 2 diabetes
mellitus; TEER: Transepithelial electrical resistance; TXNIP: Thioredoxin-
interacting protein; UBE2L6: Ubiquitin-conjugating enzyme E2L 6;
UBE2Q2: Ubiquitin-conjugating enzyme E2Q family member 2
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